Protalix BioTherapeutics (PLX) Enterprise Value (2010 - 2026)

Protalix BioTherapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$10.8 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 68.93% year-over-year to -$10.8 million in Q1 2026; TTM through Mar 2026 was -$10.8 million, a 68.93% increase from a year earlier, with the FY2025 full-year figure at -$16.3 million, up 53.22% from the prior year.
• Enterprise Value climbed to -$10.8 million in Q1 2026 per PLX's latest filing, from -$16.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$10.8 million in Q1 2026 and bottomed at -$48.5 million in Q1 2024.
• The 5-year median for Enterprise Value is -$33.0 million (2023), against an average of -$32.4 million.
• Across the five-year window, Enterprise Value slumped 100.9% in 2023 and soared 68.93% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$22.2 million in 2022, then tumbled by 100.9% to -$44.6 million in 2023, then increased by 21.84% to -$34.8 million in 2024, then soared by 53.22% to -$16.3 million in 2025, then jumped by 33.76% to -$10.8 million in 2026.
• Per Business Quant, the three latest PLX Enterprise Value figures stand at -$10.8 million (Q1 2026), -$16.3 million (Q4 2025), and -$29.4 million (Q3 2025).